Header Logo

Connection

C OSBORNE to Receptors, Progesterone

Back to Details
This is a "connection" page, showing publications C OSBORNE has written about Receptors, Progesterone.
C OSBORNE
Connection Strength
1.896
Receptors, Progesterone
  1. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
    View in: PubMed
    Score: 0.188
  2. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
    View in: PubMed
    Score: 0.184
  3. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
    View in: PubMed
    Score: 0.178
  4. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000 Mar 20; 89(2):111-7.
    View in: PubMed
    Score: 0.125
  5. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.109
  6. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51(3):227-38.
    View in: PubMed
    Score: 0.107
  7. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013 Jan; 24(1):47-53.
    View in: PubMed
    Score: 0.074
  8. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul; 134(7):e48-72.
    View in: PubMed
    Score: 0.064
  9. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 06; 134(6):907-22.
    View in: PubMed
    Score: 0.063
  10. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 01; 28(16):2784-95.
    View in: PubMed
    Score: 0.063
  11. Megestrol acetate in breast cancer--a panel discussion. Breast Cancer Res Treat. 1989 Oct; 14(1):33-8.
    View in: PubMed
    Score: 0.061
  12. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35.
    View in: PubMed
    Score: 0.046
  13. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
    View in: PubMed
    Score: 0.046
  14. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol. 1985 Sep; 12(3):317-26.
    View in: PubMed
    Score: 0.046
  15. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
    View in: PubMed
    Score: 0.044
  16. Hormone receptors in the management of breast cancer. Tex Med. 1984 Nov; 80(11):30-2.
    View in: PubMed
    Score: 0.043
  17. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 01; 22(9):1605-13.
    View in: PubMed
    Score: 0.042
  18. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9.
    View in: PubMed
    Score: 0.039
  19. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15; 46(12 Suppl):2884-8.
    View in: PubMed
    Score: 0.033
  20. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar; 16(3):994-9.
    View in: PubMed
    Score: 0.027
  21. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol. 1997 May; 15(5):1916-22.
    View in: PubMed
    Score: 0.026
  22. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May; 44(1):65-74.
    View in: PubMed
    Score: 0.026
  23. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.
    View in: PubMed
    Score: 0.022
  24. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 04; 86(9):705-12.
    View in: PubMed
    Score: 0.021
  25. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
    View in: PubMed
    Score: 0.019
  26. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84.
    View in: PubMed
    Score: 0.018
  27. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16; 83(20):1477-82.
    View in: PubMed
    Score: 0.017
  28. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063.
    View in: PubMed
    Score: 0.015
  29. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res. 1989; 32 Suppl 1:221-2.
    View in: PubMed
    Score: 0.014
  30. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987 Aug; 23(8):1189-96.
    View in: PubMed
    Score: 0.013
  31. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-21.
    View in: PubMed
    Score: 0.013
  32. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.012
  33. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.
    View in: PubMed
    Score: 0.012
  34. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 01; 23(25):5973-82.
    View in: PubMed
    Score: 0.011
  35. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct; 2(10):1102-9.
    View in: PubMed
    Score: 0.011
  36. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
    View in: PubMed
    Score: 0.010
  37. Steroid hormone receptors in the management of human breast cancer. Ann Clin Res. 1980 Oct; 12(5):202-7.
    View in: PubMed
    Score: 0.008
  38. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21.
    View in: PubMed
    Score: 0.008
  39. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
    View in: PubMed
    Score: 0.008
  40. Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979 May; 130(5):401-7.
    View in: PubMed
    Score: 0.007
  41. The use of stero?d hormone receptors in the treatment of human breast cancer: a review. Bull Cancer. 1979; 66(3):203-9.
    View in: PubMed
    Score: 0.007
  42. Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am. 1978 Aug; 58(4):777-88.
    View in: PubMed
    Score: 0.007
  43. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr; 3(4):593-600.
    View in: PubMed
    Score: 0.006
  44. Steroid hormone receptors and carcinoma of the breast. Am J Physiol. 1982 Aug; 243(2):E99-102.
    View in: PubMed
    Score: 0.002
  45. Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab. 1980 Jul; 9(2):361-8.
    View in: PubMed
    Score: 0.002
  46. In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med. 1977 Jan 20; 296(3):154-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.